{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["1(3)"],"submitter":["Duhrsen U"],"pubmed_abstract":["The PETAL (Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas) trial investigated whether treatment intensification after 2 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP; plus rituximab [R] for CD20<sup>+</sup> lymphomas) improved survival in aggressive non-Hodgkin lymphoma. A total of 754 patients (87.5%) had a negative and 108 (12.5%) had a positive interim positron emission tomography (iPET) scan. iPET-positive patients were randomly assigned to receive another 6 (R-)CHOP cycles or 6 blocks of a more intensive protocol. Interim PET-negative patients received another 4 cycles of R-CHOP with or without 2 additional doses of R. After a median follow-up of 4 years, treatment intensification had not improved outcome. These results wer"],"journal":["Blood neoplasia"],"pagination":["100018"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12082160"],"repository":["biostudies-literature"],"pubmed_title":["Response-guided first-line therapy and treatment of relapse in aggressive lymphoma: 10-year follow-up of the PETAL trial."],"pmcid":["PMC12082160"],"pubmed_authors":["Kneba M","Romer W","Stark U","Mesters R","Mahlmann S","Moorahrend E","Petrasch S","Kloke O","Wilop S","Selbach J","Keller U","Behringer D","Hahn D","Spohn C","Brenner W","Germing U","Karsten IE","Fett W","Hoffkes HG","Limmroth C","Beck C","Trenn G","Schwalenberg M","Martens UM","Neuhauser M","Hohler T","Niederwieser D","Strumberg D","Muller-Tidow C","Duhrsen U","Schafer W","Platzbecker U","Klapper W","Popperl G","von Verschuer U","Link H","Klein M","Freesmeyer M","de Wit M","Hochhaus A","La Rosee P","Klein A","Scherag A","Schroers R","Kotzerke J","Grube M","PETAL Trial Investigators","Schutte J","Grieshammer M","Witzens-Harig M","Kreisel-Bustgens C","Reimer P","Dienst A","Prange-Krex G","Nonnemacher M","Marienhagen J","Baldus C","Rekowski J","Grigoleit GU","Schmalz O","Plotkin M","Steiniger H","Held G","Held H","Gaska T","Weissinger F","Schwarzer A","Maschmeyer G","Worns MA","Franzius C","Hautzel H","Holzinger J","Herr W","Tometten M","Haberkorn U","Moeller R","Heil G","Nyuyki F","Buckner U","Raghavachar A","Heuser M","Runde V","Brink I","Jockel KH","Balleisen JS","Nuckel H","Krohn T","Hertenstein B","Giagounidis A","Jordan K","Sudhoff T","Bernhard H","Weckesser M","Sandmann M","Bockisch A","Heike M","Korfel A","Hertel A","Lutzen U","Naumann R","Larisch R","Bengel FM","Fricke E","Chemnitz JM","Schulte K","Kroschinsky F","Huttmann A","Kofahl-Krause D","Stephany M","Kluge R","Durk H"],"additional_accession":[]},"is_claimable":false,"name":"Response-guided first-line therapy and treatment of relapse in aggressive lymphoma: 10-year follow-up of the PETAL trial.","description":"The PETAL (Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas) trial investigated whether treatment intensification after 2 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP; plus rituximab [R] for CD20<sup>+</sup> lymphomas) improved survival in aggressive non-Hodgkin lymphoma. A total of 754 patients (87.5%) had a negative and 108 (12.5%) had a positive interim positron emission tomography (iPET) scan. iPET-positive patients were randomly assigned to receive another 6 (R-)CHOP cycles or 6 blocks of a more intensive protocol. Interim PET-negative patients received another 4 cycles of R-CHOP with or without 2 additional doses of R. After a median follow-up of 4 years, treatment intensification had not improved outcome. These results wer","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Sep","modification":"2026-06-01T11:40:05.968Z","creation":"2026-04-08T11:57:31.607Z"},"accession":"S-EPMC12082160","cross_references":{"pubmed":["40453056"],"doi":["10.1016/j.bneo.2024.100018"]}}